Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin. [electronic resource]
Producer: 20190122Description: e0199810 p. digitalISSN:- 1932-6203
- Actinobacteria -- drug effects
- Anti-Bacterial Agents -- pharmacology
- Benzimidazoles -- pharmacology
- Clostridioides difficile -- drug effects
- Clostridium Infections -- drug therapy
- Cohort Studies
- DNA, Bacterial -- chemistry
- Discriminant Analysis
- Feces -- microbiology
- Firmicutes -- drug effects
- Gastrointestinal Microbiome -- drug effects
- Humans
- Principal Component Analysis
- Proteobacteria -- drug effects
- Pyridines -- pharmacology
- Vancomycin -- pharmacology
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.